Table 1.
Treatment groups including mouse strain, animal number per group, dietary treatment, abbreviations of OPN-derived peptide-based vaccines, amino acid sequences and description of vaccines.
| Model | Genotype | Number of animals | Dietary treatment | ID No | Amino acid sequence | Description |
|---|---|---|---|---|---|---|
| DIO | WT | 15 | HF | Control pep 1 | C-LYRGLAS-COO | scrambled |
| cardio-metabolic | Ldlr–/– | 15 | DDC | Control pep 1 | C-LYRGLAS-COO | scrambled |
| DIO | WT | 15 | HF | Control pep 2 | C-GYSAGLD-COO | scrambled |
| DIO | WT | 15 | HF | Peptide 1 | C-LAYGLR-COO | free thrombin cleavage site |
| cardio-metabolic | Ldlr–/– | 15 | DDC | Peptide 1 | C-LAYGLR-COO | free thrombin cleavage site |
| DIO | WT/ | 15 | HF | Peptide 2 | C-PTVDVPNGRGDS-NH2 | GRGDS in OPN context |
| cardio-metabolic | Ldlr–/– | 15 | DDC | Peptide 2 | C-PTVDVPNGRGDS-NH2 | GRGDS in OPN context |
| DIO | WT | 15 | HF | Peptide 3 | C-GDSLAYG-COO | free MMP cleavage site |
| cardio-metabolic | Ldlr–/– | 15 | DDC | Peptide 3 | C-GDSLAYG-COO | free MMP cleavage site |
| DIO | WT | 15 | HF | Peptide 4 | C-RGDSLAYG-COO | free MMP cleavage site |
| DIO | WT | 15 | LF | PBS | ||
| DIO | WT | 15 | HF | PBS | ||
| cardio-metabolic | Ldlr–/– | 15 | NC | PBS | ||
| cardio-metabolic | Ldlr–/– | 15 | DDC | PBS | ||
| DIO | WT | 15 | LF | Adj-KLH | ||
| DIO | WT/ | 15 | HF | Adj-KLH | ||
| cardio-metabolic | Ldlr–/– | 15 | NC | Adj-KLH | ||
| cardio-metabolic | Ldlr–/– | 15 | DDC | Adj-KLH |
DIO = diet-induced obesity; WT = wild-type mice; Ldlr–/– = low-density lipoprotein receptor knock-out; HF = high-fat diet; DDC = sucrose-enriched high-fat diet with cholesterol; LF = low-fat diet; NC = normal chow; Adj = adjuvant; OPN = osteopontin; MMP = matrix metalloproteinase.